Balaji Amines Ltd Q4 FY2025 Concall Summary

Key Takeaways

• A reset year, with a volume-led recovery bet: Consolidated revenue fell ~14% YoY to ₹1,430 crores and EBITDA margin compressed to 19%, but management guided for minimum 10–12% volume growth in FY26 as new plants come online.
• The subsidiary is the swing factor: Balaji Speciality Chemicals (BSC) dragged on consolidated performance due to Chinese dumping and brownfield disruption; management expects Unit I modifications to finish by Q1 FY27 and Unit II to commission at least one or two plants by end-FY26, targeting a combined ₹500–700 cr top line in FY27.
• A pipeline of approvals, not just projects: DME, Isopropyl Amines, and pharma-grade PG are all built and waiting on regulatory clearances (PESO, MPCB, pharma license), making the near-term revenue trajectory contingent on bureaucratic timelines rather than execution.
• Pricing pressure is structural, not cyclical: Chinese dumping in EDA and DMF forced the company to run plants at a loss to build an antidumping case; management is pursuing government intervention while redirecting capacity toward higher-value derivatives.
• What to watch next quarter: Whether PESO approval for DME arrives and unlocks the 50% utilization target, whether Isopropyl Amines receives MPCB consent to operate within the promised week, and whether the recent raw material price spike from the Iran-Israel situation reverses or persists.

The Subsidiary Overhang: Why FY25 Was Weak

• Two structural headwinds hit simultaneously: Chinese dumping prevented BSC from running its EDA plant at full capacity, while brownfield modifications to shift the product mix toward higher-value amines (PIP, DETA, TETA, TEPA) disrupted existing operations.
• EDA plant utilization collapsed: The plant was shut for some time due to dumping and competition; it is now running at only 40–50% while modifications are underway to minimize EDA output and increase the portfolio of other derivatives.
• The debottlenecking timeline slipped: In November 2024, management guided that debottlenecking would complete in 4–6 months; the FY25 presentation now shows the brownfield project commissioning in FY27. Management explained that partial debottlenecking is done and works are ongoing, but did not directly reconcile the discrepancy.
• The recovery math is back-end loaded: Management expects all brownfield works to finish in the next 6–7 months, with full-fledged commencement by Q1 FY27. Unit II (greenfield) faces a 2–3 month delay from rains, with at least one or two plants commissioning by end-FY26.
• FY27 subsidiary top-line ambition: Unit I is targeted at a minimum ₹200–300 cr, Unit II at another ₹300–400 cr, implying a consolidated subsidiary contribution of ₹500–700 cr in FY27.
• Technology sourcing is sensitive: The Sodium Cyanide technology was developed by taking basic in-house know-how from outside the country, Indianizing it, and doing all detailing, engineering, and equipment design in-house. Management declined to name the technology partner until after commissioning.

Reddy: "This Sodium Cyanide is a technology that we very closely target, which is having very few people. And we have taken some basic in-house know-how from the outside country, which has been Indianized and detailing, engineering and designing of the equipment is done by the in-house."

The Approval Gate: Projects Built, Revenue Waiting

• DME is the largest near-term opportunity held up by regulation: The plant is ready but cannot start because DME is a new product requiring PESO to create a product code, approve bulk storage tanks (at both Balaji's end and the customer's end), issue road tanker permissions, and finalize cylinder permissions. Road tanker and cylinder permissions are partly received.
• Management's DME utilization path: 50% capacity (50,000 tons) this year, scaling to 70% (70,000 tons) next year, at approximately ₹70–75 per kg, implying a material revenue contribution if approvals come through.
• Three demand channels are being built in parallel: (1) Working with the Government of India to mandate 20% DME blending into LPG by all oil companies; (2) replacing the entire aerosol market once PESO permission is received; (3) commercial hotel and industrial use, which is viable without any permissions.
• Isopropyl Amines is a matter of days, not months: The plant is ready and management expects MPCB consent to operate within a week, making this the nearest-term commissioning catalyst.
• Pharma-grade PG unlocks the PG/DMC plant: The company has applied for a pharmaceutical-grade Propylene Glycol license; once received, the plant can survive at 60–70% capacity even without battery chemical demand materializing.
• Electronic DMC is in trial phase: One ISO tank has been delivered to a battery chemical manufacturer, and trial orders of 50–60 tons have been given to another customer, with activity starting only in the last two weeks. NMP battery grade has also seen one ISO tank sent for trials.

Reddy: "Since it is the first time the product, it will start right from the creating code of the product for applying for the PESO license. That is number one, which is completed. Then we will have to apply for the storage tank, bulk storage tank at our end. Second, bulk storage tank for the customer and also you need to have the guidelines in place. And thirdly, road tankers permission. Fourth, cylinders permission is partly done."

The Antidumping Playbook: Running at a Loss to Build a Case

• DMF strategy is deliberate loss-making: Management ran the DMF plant at full capacity even when it was making losses because Indian antidumping rules require proving injury over one or two financial years before a case can be filed. The company is currently not making eligible losses, running at 40% capacity and increasing to 60–80%, and will file for antidumping if losses recur.
• EDA antidumping is already in process: An investigation is underway with the government, providing a potential structural remedy to the Chinese dumping that has depressed subsidiary utilization.
• The competitive divergence is product-mix driven: When asked why a close competitor showed growth and margin improvement in their standalone business while Balaji declined, management attributed it to different product mixes, noting that in any given financial year one company's mix may perform better than another's.

Reddy: "We started running at full capacity when it made loss also because right or wrong, with our government, we have to prove ourselves by making the losses at least 1, 2 financial years, we have to make the losses. Then you are eligible for the — filing of the antidumping."

Demand & Pricing: A Fragile Recovery

• April and May showed broad-based improvement: Demand and pricing were positive across all products, with pharmaceutical demand stable and agrochemicals showing marginal YoY increase.
• The last 1–1.5 weeks reversed the trend: Raw material prices spiked due to the Israel-Iran war situation and its impact on petrochemicals, creating pricing pressure. Demand is present but unit prices are rising, compressing margins.
• The Q4 FY25 improvement was relative, not absolute: The quarter improved versus earlier quarters due to relatively favorable global microeconomic conditions and a gradual uptick in volumes, but FY25 as a whole still saw revenue decline from ₹1,671 cr to ₹1,430 cr.
• Dimethylamine hydrochloride is a bright spot: The product is running at full capacity because it is used in life-saving drugs; only pricing pressure remains a concern.

Reddy: "But demand is there, only unit prices are going up because of this."

Capex, Capitalization & Balance Sheet

• Standalone capex is capped at ₹200 cr, with all projects funded through internal accruals, highlighting the company's stated financial discipline.
• Subsidiary capex is the larger commitment: Phase I requires ₹300–350 cr, Phase II another ₹350–400 cr, with Phase I expected to commission by end-FY26 and Phase II after FY27.
• A capitalization anomaly raised by an analyst: Per an analyst's math, ₹440 cr of capex was spent but CWIP increased only ₹120 cr, implying ₹320 cr was capitalized, yet the top line declined 40%. Management explained that plants are partially running but not at full capacity, and capitalization occurs once even 100 kgs are produced.
• Consolidated net debt by March 2027 is expected to be modest: Possibly ₹100–150 cr at the subsidiary level, with total debt of only ₹50–100 cr, implying the company expects internal accruals to cover the majority of the ₹650–750 cr subsidiary capex program.
• State government incentives are already flowing: Some cash has been received in the current financial year for both Balaji Amines and its subsidiary; incentives are paid over 7 years based on 50% of GST paid on sales.

New Product Pipeline & Market Access

• Acetonitrile expansion is a FY27 story: Capacity expansion to 60 MT/day at Unit III, Chincholi, is expected to commission in FY27, with management targeting 19–20% EBITDA margins. Current volumes in FY25 were negligible.
• N-Butylamine is partly operational, waiting on NBPT: The butylamine plant is running partly; the NBPT plant (2,500 TPA) will be taken up in the next financial year, after which butylamines can operate at more than 80% capacity.
• REACH registration is progressing for export access: N-Butylamine samples have been sent outside the country for evaluation, and REACH registration has been paid for DMC, signaling intent to access regulated export markets.
• N-Methyl Morpholine commissioning is expected in FY26, adding another specialty amine to the portfolio.
• Solar power is already reducing costs: The first phase (8 MW DC) was commissioned in April 2025 and is substantially reducing power cost across all plants.

Reddy: "We will not let you down. And thank you once again. We'll put all our efforts to make this company to highest level of the expectations."

Guidance & Commitments

Key Metrics